Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Control Form 5 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Influence of Edible Marijuana on Endurance Exercise Performance

NCT05192239
View directory record Official record
Conditions
Endurance Exercise
Interventions
THC 5, Placebo
Drug
Lead sponsor
Christopher Bell
Other
Eligibility
21 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 30, 2026, 10:46 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Glutathione vs. Curcumin Clinical Trial

NCT02848417
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Curcumin, Glutathione, Placebo
Drug · Other
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
35 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 30, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

NCT05276401
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Jonesboro, Arkansas • Fresno, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

NCT01500109
View directory record Official record
Conditions
Cleft Palate
Interventions
Oral acetaminophen, Ofirmev®, Opioid only
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
5 Months to 5 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

NCT06315335
View directory record Official record
Conditions
Healthy Participants
Interventions
UCB9741, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Random Nicotine Delivery on Smoking Cessation

NCT03674970
View directory record Official record
Conditions
Smoking Cessation, Cigarette Smoking, Smoking (Tobacco) Addiction
Interventions
Nicotine Film
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

NCT04796207
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions
Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 30, 2026, 10:46 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

NCT07079761
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
Behavioral · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

NCT01240980
View directory record Official record
Conditions
Diabetes
Interventions
BMS-903452, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease

NCT00090402
View directory record Official record
Conditions
Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia, Inflammation
Interventions
Fish Oil, Lipoic Acid, Fish Oil Placebo, Lipoic Acid Placebo
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Shigella Vaccine and Challenge

NCT04242264
View directory record Official record
Conditions
Immunisation, Shigella Infection
Interventions
Placebo, Shigella sonnei strain 53G, WRSs2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Decatur, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia

NCT01232790
View directory record Official record
Conditions
Schizophrenia
Interventions
N-Acetylcysteine, Placebo
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 30, 2026, 10:46 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood

NCT01508741
View directory record Official record
Conditions
Insomnia, Nocturnal Awakening, Irritability, Coping Behavior, Stress
Interventions
5-Aminolevulinic Acid (5-ALA), Placebo
Dietary Supplement
Lead sponsor
University of Hawaii
Other
Eligibility
40 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse

NCT01987089
View directory record Official record
Conditions
Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

NCT00749658
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Withdrawal
Interventions
Bupropion, Varenicline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Terminated Phase 3 Interventional Results available

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

NCT02853604
View directory record Official record
Conditions
High Risk Cervical Cancer, Advanced Cervical Cancer
Interventions
ADXS11-001, Placebo
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 30, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

NCT00675025
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

NCT01606384
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

NCT04575597
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 30, 2026, 10:46 PM EDT